8/25/08 VGX Pharmaceuticals announces the publication of pivotal data from its LifeTide™ SW 5 studies, which led to the approval in Australia of the GHRH gene therapy product for pigs
7/7/08 Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement
7/7/08 VGX Pharmaceuticals announces the discontinuation of its PICTOVIR™ Program
7/1/08 VGX Pharmaceuticals receives FDA approval of IND for novel DNA vaccine for cervical cancer therapy
6/25/08 VGX announces publication of preclinical data for the Company’s avian flu vaccine candidate in PLoS ONE journal
6/23/08 VGX Licenses Additional DNA Vaccines Technology from the University of Pennsylvania
6/17/08 VGX Gene Therapy Technology Featured at the 90th Annual Endocrine Society Meeting
6/12/08 VGX Collaborators to present Chikungunya Vaccine Research at the 13th International Congress on Infectious Diseases
6/3/08 VGX Pharmaceuticals Announces Reorganization of its Manufacturing Assets
6/2/08 VGX Pharmaceuticals Announces Management Promotion
5/28/08 VGX Pharmaceuticals to Make Multiple Presentations at the American Society of Gene Therapy Meeting Showcasing its Patented CELLECTRA® Electroporation Device for DNA Delivery and its DNA Manufacturing Process.
5/22/08 VGX Pharmaceuticals announces publication in Molecular Therapy regarding the Company’s GHRH gene therapy product
5/19/08 VGX Pharmaceuticals announces filings of two separate INDs covering novel DNA vaccines: one for cervical cancer therapy (VGX-3100) and one for avian influenza (VGX-3400)
5/12/08 VGX Pharmaceuticals signs multi-year production agreement with the United Kingdom Cystic Fibrosis Gene Therapy Consortium
5/5/08 VGX Pharmaceuticals to present at the 11th Annual Conference on Vaccine Research
4/16/08 VGX Pharmaceuticals announces a license agreement with VGX International to use CELLECTRA™ electroporation device to develop new DNA-based vaccines and therapies
2/29/08 VGX Pharmaceuticals Co-Founder Professor David B. Weiner to Chair the First DNA Vaccines Conference in Asia
2/8/08 VGX Pharmaceuticals announces the IND filing of VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia
2/5/08 VGX Pharmaceuticals announces Initiation of VGX-cGMP Manufactured Plasmid Products in Clinical Use by Partners
1/21/08 VGX Pharmaceuticals Submits Device Master File to FDA for CELLECTRA™ Electroporator
1/14/08 VGX Pharmaceuticals receives FDA clearance to commence clinical trials of VGX-1027, a novel oral drug with potent anti-inflammatory activity
1/9/08 VGX Animal Health announces approval of LifeTide™ SW 5 - World’s First and Only Approved DNA Therapy for Food Animals


 
 
© 2008 VGX™ Pharmaceuticals. All rights reserved.